{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:37:06Z","timestamp":1775068626168,"version":"3.50.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02019-4","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:02:35Z","timestamp":1682064155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies"],"prefix":"10.1007","volume":"40","author":[{"given":"Mohammed Hikmat","family":"Faeq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysoon","family":"Al-Haideri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talar Ahmad Merza","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad","family":"gharebakhshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faroogh","family":"Marofi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-1922","authenticated-orcid":false,"given":"Safa","family":"Tahmasebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadan","family":"Modaresahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"issue":"3","key":"2019_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA A Cancer J Clin"},{"issue":"20","key":"2019_CR2","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.3390\/ijms21207504","volume":"21","author":"C Nastasi","year":"2020","unstructured":"Nastasi C, Mannarino L, D\u2019Incalci M. DNA damage response and immune defense. Int J Mol Sci. 2020;21(20):7504.","journal-title":"Int J Mol Sci"},{"key":"2019_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1871520615666150824153523","volume":"16","author":"SM Candeias","year":"2016","unstructured":"Candeias SM, Gaipl US. The immune system in cancer prevention, development and therapy. Anticancer Agents Med Chem. 2016;16:101\u20137.","journal-title":"Anticancer Agents Med Chem"},{"key":"2019_CR4","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3389\/fimmu.2018.01717","volume":"9","author":"R Elahi","year":"2018","unstructured":"Elahi R, Khosh E, Tahmasebi S, Esmaeilzadeh A. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol. 2018;9:1717.","journal-title":"Front Immunol"},{"key":"2019_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","volume":"15","author":"S Tahmasebi","year":"2019","unstructured":"Tahmasebi S, Elahi R, Esmaeilzadeh A. Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Stem Cell Rev Rep. 2019;15:619\u201336.","journal-title":"Stem Cell Rev Rep"},{"key":"2019_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2741\/4780","volume":"24","author":"M Coscia","year":"2019","unstructured":"Coscia M, Vitale C, Cerrano M, Maffini E, Giaccone L, et al. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives. Front Biosci. 2019;24:1284\u2013315.","journal-title":"Front Biosci"},{"issue":"8","key":"2019_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/annonc\/mds256","volume":"23","author":"OJ Finn","year":"2012","unstructured":"Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(8):6\u20139. https:\/\/doi.org\/10.1093\/annonc\/mds256.","journal-title":"Ann Oncol"},{"key":"2019_CR8","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904\u201312.","journal-title":"Oncogene"},{"key":"2019_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","volume":"16","author":"TL Whiteside","year":"2006","unstructured":"Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16:3\u201315.","journal-title":"Semin Cancer Biol"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00262-011-1181-5","volume":"61","author":"AA Hurwitz","year":"2012","unstructured":"Hurwitz AA, Watkins SK. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother. 2012;61:289\u201393.","journal-title":"Cancer Immunol Immunother"},{"key":"2019_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cellimm.2015.09.011","volume":"299","author":"S Ostrand-Rosenberg","year":"2016","unstructured":"Ostrand-Rosenberg S. Tolerance and immune suppression in the tumor microenvironment. Cell Immunol. 2016;299:23\u20139.","journal-title":"Cell Immunol"},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Rahman HS, Al-Obaidi ZMJ, Jalil AT, Abdelbasset WK, et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res Ther. 2021;12:465.","journal-title":"Stem Cell Res Ther"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13287-021-02283-z","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Tahmasebi S, Rahman HS, Kaigorodov D, Markov A, et al. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Res Ther. 2021;12:217.","journal-title":"Stem Cell Res Ther"},{"key":"2019_CR14","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3389\/fimmu.2020.01568","volume":"11","author":"MK Jakobsen","year":"2020","unstructured":"Jakobsen MK, Gjerstorff MF. CAR T-Cell Cancer Therapy Targeting Surface Cancer\/Testis Antigens. Front Immunol. 2020;11:1568.","journal-title":"Front Immunol"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov"},{"key":"2019_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends Immunol. 2015;36:494\u2013502.","journal-title":"Trends Immunol"},{"issue":"22","key":"2019_CR17","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.3390\/ijms21228655","volume":"21","author":"WY Lin","year":"2020","unstructured":"Lin WY, Wang HH, Chen YW, Lin CF, Fan HC, Lee YY. Gene modified CAR-T cellular therapy for hematologic malignancies. Int J Mol Sci. 2020;21(22):8655.","journal-title":"Int J Mol Sci"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cgt.2015.5","volume":"22","author":"BL Levine","year":"2015","unstructured":"Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22:79\u201384.","journal-title":"Cancer Gene Ther"},{"key":"2019_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011. https:\/\/doi.org\/10.1126\/scitranslmed.3002842.","journal-title":"Sci Transl Med"},{"key":"2019_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1055\/s-0038-1656035","volume":"77","author":"CS Engstad","year":"1997","unstructured":"Engstad CS, Gutteberg TJ, Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost. 1997;77:690\u20136.","journal-title":"Thromb Haemost"},{"key":"2019_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1006\/mthe.1999.0012","volume":"1","author":"MC Jensen","year":"2000","unstructured":"Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1:49\u201355.","journal-title":"Mol Ther"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164\u201381.","journal-title":"Curr Opin Biotechnol"},{"key":"2019_CR24","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jcyt.2015.05.013","volume":"17","author":"S Ramanayake","year":"2015","unstructured":"Ramanayake S, Bilmon I, Bishop D, Dubosq MC, Blyth E, et al. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy. 2015;17:1251\u201367.","journal-title":"Cytotherapy"},{"key":"2019_CR25","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J, Chen EY, Wood BL, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261\u201371.","journal-title":"Blood"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/cgt.2014.78","volume":"22","author":"AD Kaiser","year":"2015","unstructured":"Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 2015;22:72\u20138.","journal-title":"Cancer Gene Ther"},{"key":"2019_CR28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","volume":"15","author":"B Tumaini","year":"2013","unstructured":"Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy. 2013;15:1406\u201315.","journal-title":"Cytotherapy"},{"key":"2019_CR29","first-page":"18","volume":"13","author":"M Janas","year":"2015","unstructured":"Janas M, Nunes C, Marenghi A, Sauvage V, Davis B, et al. Perfusion\u2019s role in maintenance of high-density T-cell cultures. BioProcess Int. 2015;13:18\u201326.","journal-title":"BioProcess Int"},{"key":"2019_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discovery"},{"key":"2019_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/trf.14365","volume":"58","author":"J Kwoczek","year":"2018","unstructured":"Kwoczek J, Riese SB, Tischer S, Bak S, Lahrberg J, et al. Cord blood-derived T cells allow the generation of a more na\u00efve tumor-reactive cytotoxic T-cell phenotype. Transfusion. 2018;58:88\u201399.","journal-title":"Transfusion"},{"key":"2019_CR32","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097\u2013100.","journal-title":"Science"},{"key":"2019_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","volume":"28","author":"JE Rubnitz","year":"2010","unstructured":"Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol\u202f: Off J Amr Soci Clin Oncol. 2010;28:955\u20139.","journal-title":"J Clin Oncol : Off J Amr Soci Clin Oncol"},{"key":"2019_CR34","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.","journal-title":"EBioMedicine"},{"key":"2019_CR35","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652\u20138.","journal-title":"Leukemia"},{"key":"2019_CR36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Sch\u00f6nfeld","year":"2015","unstructured":"Sch\u00f6nfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330\u20138.","journal-title":"Mol Ther"},{"key":"2019_CR37","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2017.00683","volume":"8","author":"M Messaoudene","year":"2017","unstructured":"Messaoudene M, Frazao A, Gavlovsky PJ, Toubert A, Dulphy N, Caignard A. Patient\u2019s natural killer cells in the era of targeted therapies: role for tumor killers. Front Immunol. 2017;8:683.","journal-title":"Front Immunol"},{"key":"2019_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fonc.2019.00051","volume":"9","author":"G Nayyar","year":"2019","unstructured":"Nayyar G, Chu Y, Cairo MS. Overcoming resistance to natural killer cell based immunotherapies for solid tumors. Front Oncol. 2019;9:51.","journal-title":"Front Oncol"},{"key":"2019_CR39","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1056\/NEJMoa041469","volume":"351","author":"V Rocha","year":"2004","unstructured":"Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276\u201385.","journal-title":"N Engl J Med"},{"key":"2019_CR40","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","volume":"113","author":"Y Atsuta","year":"2009","unstructured":"Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, et al. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009;113:1631\u20138.","journal-title":"Blood"},{"key":"2019_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","volume":"13","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13:168.","journal-title":"J Hematol Oncol"},{"key":"2019_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00283","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00283.","journal-title":"Front Immunol"},{"key":"2019_CR43","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1073\/pnas.89.4.1492","volume":"89","author":"P Moingeon","year":"1992","unstructured":"Moingeon P, Lucich JL, McConkey DJ, Letourneur F, Malissen B, et al. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proc Natl Acad Sci USA. 1992;89:1492\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019_CR44","doi-asserted-by":"crossref","unstructured":"Buller CW, Mathew PA, Mathew SO. 2020. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. 12: 1755","DOI":"10.3390\/cancers12071755"},{"key":"2019_CR45","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","volume":"194","author":"K T\u00f6pfer","year":"2015","unstructured":"T\u00f6pfer K, Cartellieri M, Michen S, Wiedemuth R, M\u00fcller N, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194:3201\u201312.","journal-title":"J Immunol"},{"key":"2019_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ni929","volume":"4","author":"DD Billadeau","year":"2003","unstructured":"Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell\u2013mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4:557\u201364.","journal-title":"Nat Immunol"},{"key":"2019_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720501","author":"H Lu","year":"2021","unstructured":"Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.720501.","journal-title":"Front Oncol"},{"key":"2019_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","volume":"16","author":"M Themeli","year":"2015","unstructured":"Themeli M, Rivi\u00e8re I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015;16:357\u201366.","journal-title":"Cell Stem Cell"},{"key":"2019_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/imt-2016-0127","volume":"9","author":"F Anwer","year":"2017","unstructured":"Anwer F, Shaukat AA, Zahid U, Husnain M, McBride A, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy. 2017;9:123\u201330.","journal-title":"Immunotherapy"},{"key":"2019_CR50","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293\u2013301.","journal-title":"Blood"},{"key":"2019_CR51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/bjh.14570","volume":"177","author":"N Shah","year":"2017","unstructured":"Shah N, Li L, McCarty J, Kaur I, Yvon E, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017;177:457\u201366.","journal-title":"Br J Haematol"},{"key":"2019_CR52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood.2019000621","volume":"135","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bjordahl R, Gaidarova S, Rogers P, et al. Pluripotent stem cell\u2013derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 2020;135:399\u2013410.","journal-title":"Blood"},{"key":"2019_CR53","doi-asserted-by":"publisher","first-page":"561553","DOI":"10.3389\/fimmu.2020.561553","volume":"11","author":"BH Goldenson","year":"2020","unstructured":"Goldenson BH, Zhu H, Wang YM, Heragu N, Bernareggi D, et al. Umbilical cord blood and ipsc-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles. Front Immunol. 2020;11:561553.","journal-title":"Front Immunol"},{"key":"2019_CR54","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:1563\u201370.","journal-title":"Cytotherapy"},{"key":"2019_CR55","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147.","journal-title":"Oncoimmunology"},{"key":"2019_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018;39:167\u201376.","journal-title":"Acta Pharmacol Sin"},{"key":"2019_CR57","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187.","journal-title":"J Immunol Res"},{"key":"2019_CR58","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","volume":"18","author":"S Yu","year":"2019","unstructured":"Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18:125.","journal-title":"Mol Cancer"},{"key":"2019_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00021","author":"W Glienke","year":"2015","unstructured":"Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015. https:\/\/doi.org\/10.3389\/fphar.2015.00021.","journal-title":"Front Pharmacol"},{"key":"2019_CR60","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","volume":"22","author":"AE Hay","year":"2019","unstructured":"Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. J Med Econ. 2019;22:613\u20135.","journal-title":"J Med Econ"},{"key":"2019_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112512","volume":"146","author":"AZ Mehrabadi","year":"2022","unstructured":"Mehrabadi AZ, Ranjbar R, Farzanehpour M, Shahriary A, Dorostkar R, et al. Therapeutic potential of CAR T cell in malignancies: a scoping review. Biomed Pharmacother. 2022;146: 112512.","journal-title":"Biomed Pharmacother"},{"key":"2019_CR62","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020;26:1686\u201390.","journal-title":"Nat Med"},{"key":"2019_CR63","first-page":"2824","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, Liu D, Tian G, Courtney AN, Wei J, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood J Amr Soci Hematol. 2014;124:2824\u201333.","journal-title":"Blood J Amr Soci Hematol"},{"key":"2019_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom10020263","volume":"10","author":"DW Kim","year":"2020","unstructured":"Kim DW, Cho J-Y. Recent advances in allogeneic CAR-T cells. Biomolecules. 2020;10:263.","journal-title":"Biomolecules"},{"key":"2019_CR65","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms22031096","volume":"22","author":"R Poels","year":"2021","unstructured":"Poels R, Drent E, Lameris R, Katsarou A, Themeli M, et al. Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma. Int J Mol Sci. 2021;22:1096.","journal-title":"Int J Mol Sci"},{"key":"2019_CR66","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41467-020-14332-x","volume":"11","author":"S Fu","year":"2020","unstructured":"Fu S, He K, Tian C, Sun H, Zhu C, et al. Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells. Nat Commun. 2020;11:438.","journal-title":"Nat Commun"},{"key":"2019_CR67","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s11427-016-0348-7","volume":"59","author":"D Xie","year":"2016","unstructured":"Xie D, Zhu S, Bai L. Lactic acid in tumor microenvironments causes dysfunction of NKT cells by interfering with mTOR signaling. Sci China Life Sci. 2016;59:1290\u20136.","journal-title":"Sci China Life Sci"},{"key":"2019_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.leukres.2004.06.005","volume":"29","author":"K-i Yoneda","year":"2005","unstructured":"Yoneda K-i, Morii T, Nieda M, Tsukaguchi N, Amano I, et al. The peripheral blood V\u03b124+NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res. 2005;29:147\u201352.","journal-title":"Leuk Res"},{"key":"2019_CR69","doi-asserted-by":"publisher","first-page":"e1363139","DOI":"10.1080\/2162402X.2017.1363139","volume":"6","author":"C Fournier","year":"2017","unstructured":"Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial watch: adoptively transferred cells for anticancer immunotherapy. Oncoimmunology. 2017;6:e1363139.","journal-title":"Oncoimmunology"},{"issue":"16","key":"2019_CR70","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.3390\/ijms22168996","volume":"22","author":"T Haslauer","year":"2021","unstructured":"Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T-cell therapy in hematological malignancies. Int J Mol Sci. 2021;22(16):8996.","journal-title":"Int J Mol Sci"},{"key":"2019_CR71","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Trans Immunol. 2021;10:e1274.","journal-title":"Clin Trans Immunol"},{"key":"2019_CR72","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/CCO.0000000000000668","volume":"32","author":"MJ Kersten","year":"2020","unstructured":"Kersten MJ, Spanjaart AM, Thieblemont C. CD19-directed CAR T-cell therapy in B-cell NHL. Curr Opin Oncol. 2020;32:408\u201317.","journal-title":"Curr Opin Oncol"},{"key":"2019_CR73","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"2019_CR74","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2019_CR75","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","volume":"43","author":"EN Mugnaini","year":"2016","unstructured":"Mugnaini EN, Ghosh N. Lymphoma. Prim Care. 2016;43:661\u201375.","journal-title":"Prim Care"},{"issue":"175\u201398","key":"2019_CR76","first-page":"vii","volume":"46","author":"MJ Matasar","year":"2008","unstructured":"Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am. 2008;46(175\u201398):vii.","journal-title":"Radiol Clin North Am"},{"key":"2019_CR77","unstructured":"Xiaobin Victor Lu 2017 Chair of the Review Committee, Summary Basis for Regulatory Action\u2014Kymriah,. FDA."},{"key":"2019_CR78","unstructured":"Michael Havert 2017 Chair of the Review Committee, Summary Basis for Regulatory Action\u2014Yescarta,. FDA."},{"key":"2019_CR79","unstructured":"Kimberly LWSchultz 2021 Chair of the Review Committee, Summary Basis for Regulatory Action Template\u2014Breyanzi,. FDA."},{"key":"2019_CR80","unstructured":"Price G 2020 Chair of the Review Committee, Summary Basis for Regulatory Action\u2014Tecartus,. FDA."},{"key":"2019_CR81","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/blood.V82.2.343.343","volume":"82","author":"CH Pui","year":"1993","unstructured":"Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82:343\u201362.","journal-title":"Blood"},{"key":"2019_CR82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. Cancer J Clin. 2014;64:83\u2013103.","journal-title":"Cancer J Clin"},{"issue":"Suppl 2","key":"2019_CR83","volume":"68","author":"JH Chang","year":"2021","unstructured":"Chang JH, Poppe MM, Hua CH, Marcus KJ, Esiashvili N. Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(Suppl 2): e28371.","journal-title":"Pediatr Blood Cancer"},{"key":"2019_CR84","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099\u2013102.","journal-title":"Blood"},{"key":"2019_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cancergen.2013.01.003","volume":"206","author":"AE Rodr\u00edguez-Vicente","year":"2013","unstructured":"Rodr\u00edguez-Vicente AE, D\u00edaz MG, Hern\u00e1ndez-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet. 2013;206:49\u201362.","journal-title":"Cancer Genet"},{"key":"2019_CR86","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96:1679\u2013705.","journal-title":"Am J Hematol"},{"key":"2019_CR87","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","volume":"104","author":"L Scarf\u00f2","year":"2016","unstructured":"Scarf\u00f2 L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169\u201382.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019_CR88","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"2019_CR89","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122627","author":"MB Geyer","year":"2019","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B, Wang X, Wang Y, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL. JCI insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.122627.","journal-title":"JCI insight"},{"key":"2019_CR90","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified t cells in relapsed chronic lymphocytic leukemia. J Clin Oncol\u202f: Off J Amr Soci Clin Oncol. 2020;38:2862\u201371.","journal-title":"J Clin Oncol : Off J Amr Soci Clin Oncol"},{"key":"2019_CR91","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","volume":"26","author":"MB Geyer","year":"2018","unstructured":"Geyer MB, Rivi\u00e8re I, S\u00e9n\u00e9chal B, Wang X, Wang Y, et al. Autologous CD19-targeted CAR T CELLS in Patients with residual CLL following initial purine analog-based therapy. Mol Ther. 2018;26:1896\u2013905.","journal-title":"Mol Ther"},{"key":"2019_CR92","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res\u202f: Off J Amr Assoc Cancer Resh. 2013;19:2048\u201360.","journal-title":"Clin Cancer Res : Off J Amr Assoc Cancer Resh"},{"key":"2019_CR93","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"2019_CR94","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/bjh.13889","volume":"172","author":"D Atanackovic","year":"2016","unstructured":"Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol. 2016;172:685\u201398.","journal-title":"Br J Haematol"},{"key":"2019_CR95","unstructured":"Anna Kwilas 2021 Chair of the Review Committee,Summary Basis for Regulatory Action_ABECMA. FDA."},{"key":"2019_CR96","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12:81.","journal-title":"Stem Cell Res Ther"},{"key":"2019_CR97","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s12094-020-02490-9","volume":"23","author":"S Tahmasebi","year":"2021","unstructured":"Tahmasebi S, Elahi R, Khosh E, Esmaeilzadeh A. Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy. Clin Trans Oncol\u202f: Off Publ Fed Span Oncol Soci Nat Cancer Inst M. 2021;23:1003\u201319.","journal-title":"Clin Trans Oncol : Off Publ Fed Span Oncol Soci Nat Cancer Inst M"},{"key":"2019_CR98","unstructured":"Alkabban FM, Ferguson T. 2022. Breast Cancer. In StatPearls. Treasure Island (FL): StatPearls Publishing, Florida Copyright \u00a9 2022, StatPearls Publishing LLC"},{"key":"2019_CR99","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","volume":"20","author":"S Kakarla","year":"2014","unstructured":"Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20:151\u20135.","journal-title":"Cancer J"},{"key":"2019_CR100","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/978-981-10-6020-5_17","volume":"1026","author":"J Wang","year":"2017","unstructured":"Wang J, Zhou P. New approaches in CAR-T cell immunotherapy for breast cancer. Adv Exp Med Biol. 2017;1026:371\u201381.","journal-title":"Adv Exp Med Biol"},{"key":"2019_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126345","author":"L Wallstabe","year":"2019","unstructured":"Wallstabe L, G\u00f6ttlich C, Nelke LC, K\u00fchnemundt J, Schwarz T, et al. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.126345.","journal-title":"JCI insight"},{"issue":"12","key":"2019_CR102","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22(12):6532.","journal-title":"Int J Mol Sci"},{"key":"2019_CR103","first-page":"288","volume":"27","author":"OW Foley","year":"2013","unstructured":"Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology. 2013;27:288\u201394.","journal-title":"Oncology"},{"key":"2019_CR104","doi-asserted-by":"publisher","first-page":"64607","DOI":"10.18632\/oncotarget.19929","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu X, Cai H, Zhao L, Ning L, Lang J. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017;8:64607\u201321.","journal-title":"Oncotarget"},{"key":"2019_CR105","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.7150\/ijbs.63181","volume":"17","author":"Z Liang","year":"2021","unstructured":"Liang Z, Dong J, Yang N, Li SD, Yang ZY, et al. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer. Int J Biol Sci. 2021;17:4365\u201376.","journal-title":"Int J Biol Sci"},{"key":"2019_CR106","unstructured":"Cancer IAfRo. 2020 Global Cancer Observatory: cancer today. world health organization"},{"issue":"9","key":"2019_CR107","doi-asserted-by":"publisher","first-page":"170070","DOI":"10.1098\/rsob.170070","volume":"7","author":"S Blandin Knight","year":"2017","unstructured":"Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.","journal-title":"Open Biol"},{"key":"2019_CR108","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019;94:1623\u201340.","journal-title":"Mayo Clin Proc"},{"key":"2019_CR109","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1053\/j.seminoncol.2013.12.007","volume":"41","author":"ML Johnson","year":"2014","unstructured":"Johnson ML, Patel JD. Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer. Semin Oncol. 2014;41:93\u2013100.","journal-title":"Semin Oncol"},{"key":"2019_CR110","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero R, Devine WP. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. Surg pathol Clin. 2020;13:17\u201333.","journal-title":"Surg pathol Clin"},{"key":"2019_CR111","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/1759-7714.12765","volume":"9","author":"H Zhao","year":"2018","unstructured":"Zhao H, Ren D, Liu H, Chen J. Comparison and discussion of the treatment guidelines for small cell lung cancer. Thoracic Cancer. 2018;9:769\u201374.","journal-title":"Thoracic Cancer"},{"key":"2019_CR112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","volume":"12","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12:47.","journal-title":"J Hematol Oncol"},{"key":"2019_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.782775","author":"B-F Xiao","year":"2021","unstructured":"Xiao B-F, Zhang J-T, Zhu Y-G, Cui X-R, Lu Z-M, et al. chimeric antigen receptor t-cell therapy in lung cancer: potential and challenges. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.782775.","journal-title":"Front Immunol"},{"key":"2019_CR114","first-page":"2449","volume":"361","author":"SD Markowitz","year":"2009","unstructured":"Markowitz SD. Bertagnolli MMJNEjom. Mol Basis Colorectal Cancer. 2009;361:2449\u201360.","journal-title":"Mol Basis Colorectal Cancer"},{"key":"2019_CR115","doi-asserted-by":"publisher","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","volume":"1","author":"EJ Kuipers","year":"2015","unstructured":"Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, et al. Colorectal Cancer Nat Rev Dis Primers. 2015;1:15065.","journal-title":"Colorectal Cancer Nat Rev Dis Primers"},{"issue":"21","key":"2019_CR116","doi-asserted-by":"publisher","first-page":"11781","DOI":"10.3390\/ijms222111781","volume":"22","author":"C Aparicio","year":"2021","unstructured":"Aparicio C, Belver M, Enr\u00edquez L, Espeso F, N\u00fa\u00f1ez L, et al. Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR)-T cells. Int J Mol Sci. 2021;22(21):11781.","journal-title":"Int J Mol Sci"},{"key":"2019_CR117","doi-asserted-by":"publisher","first-page":"153303382096211","DOI":"10.1177\/1533033820962117","volume":"19","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Liu W. Pancreatic cancer: a review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat. 2020;19:1533033820962117.","journal-title":"Technol Cancer Res Treat"},{"key":"2019_CR118","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.3748\/wjg.v27.i35.5851","volume":"27","author":"V Tonini","year":"2021","unstructured":"Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol. 2021;27:5851\u201389.","journal-title":"World J Gastroenterol"},{"key":"2019_CR119","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10620-020-06183-9","volume":"66","author":"J Wu","year":"2021","unstructured":"Wu J, Cai J. Dilemma and challenge of immunotherapy for pancreatic cancer. Dig Dis Sci. 2021;66:359\u201368.","journal-title":"Dig Dis Sci"},{"key":"2019_CR120","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"2019_CR121","doi-asserted-by":"publisher","first-page":"10373","DOI":"10.3390\/ijms221910373","volume":"22","author":"P \u015aledzi\u0144ska","year":"2021","unstructured":"\u015aledzi\u0144ska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA. Prognostic and predictive biomarkers in gliomas. Int J Mol Sci. 2021;22:10373.","journal-title":"Int J Mol Sci"},{"key":"2019_CR122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-022-01513-z","volume":"21","author":"K Yang","year":"2022","unstructured":"Yang K, Wu Z, Zhang H, Zhang N, Wu W, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21:39.","journal-title":"Mol Cancer"},{"key":"2019_CR123","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603:934\u201341.","journal-title":"Nature"},{"key":"2019_CR124","volume-title":"Coronavirus Disease - COVID-19","author":"A Esmaeilzadeh","year":"2021","unstructured":"Esmaeilzadeh A, Jafari D, Tahmasebi S, Elahi R, Khosh E. Immune-Based Therapy for COVID-19. In: Rezaei N, editor. Coronavirus Disease - COVID-19. Cham: Springer International Publishing; 2021."},{"key":"2019_CR125","doi-asserted-by":"publisher","first-page":"119503","DOI":"10.1016\/j.lfs.2021.119503","volume":"277","author":"M Ghaebi","year":"2021","unstructured":"Ghaebi M, Tahmasebi S, Jozghorbani M, Sadeghi A, Thangavelu L, et al. Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. Life Sci. 2021;277:119503.","journal-title":"Life Sci"},{"key":"2019_CR126","volume-title":"Handbook of Cancer and Immunology","author":"S Tahmasebi","year":"2022","unstructured":"Tahmasebi S, Alimohammadi M, Khorasani S, Rezaei N. Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in Cancer. In: Rezaei N, editor. Handbook of Cancer and Immunology. Cham: Springer International Publishing; 2022."},{"key":"2019_CR127","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"2019_CR128","doi-asserted-by":"publisher","DOI":"10.1007\/16833_2022_64","volume-title":"Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers","author":"S Tahmasebi","year":"2022","unstructured":"Tahmasebi S, Khosh E, Rostami S, Rezaei N. Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers. Cham: Springer International Publishing; 2022."},{"key":"2019_CR129","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, maleki AH, Rostami S, et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022;22:365.","journal-title":"Cancer Cell Int"},{"key":"2019_CR130","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yu Z, Tan X, Jiang H, Xu Z, et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother Biomed Pharmacother. 2021;139:111605.","journal-title":"Biomed Pharmacother Biomed Pharmacother"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02019-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:18:05Z","timestamp":1744215485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02019-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":130,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02019-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"155"}}